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We appreciate the comments by Blake et al. [2016] regarding our
manuscript “Atypical phenotypes associated with pathogenic
CHD7 sequence variants and a proposal for broadening CHARGE
syndrome clinical diagnostic criteria” [Hale et al., 2016]. Blake et al.
emphasize (as we do in our paper) that clinicians need to be aware
of the wide variety of clinical presentations associated with
CHARGE syndrome. They also question the appropriateness of
our minor criteria and how they influence clinical diagnosis
and care. We welcome these questions and provide clarification
in order to promote discussion and to ensure that these
proposed criteria are accessible to clinicians outside the genetics
community.
The most recent clinical diagnostic criteria for CHARGE,
established by Verloes [2005], were robust and comprehensive,
and allowed for wide variability in clinical presentation [Verloes,
2005]. The Verloes criteria built upon earlier criteria by
Blake et al. [1998], and included the same major criteria as we
propose in our manuscript. In contrast to earlier diagnostic
criteria (and perhaps a source of confusion), our proposed
“minor criteria” are better thought of as associated features,
since their presence or absence does not influence the final
diagnosis of CHARGE syndrome. For example, “cranial nerve
(CN) dysfunction” is a minor criterion since it encompasses
dysfunction of cranial nerves other than coloboma (CN-II) or
hearing loss (CN-VIII), both of which are major criteria. Man-
ifestations of other CN dysfunction (e.g., CNs-V, VII, IX, and X),
including dysphagia, and anosmia/hyposmia (CN-I) are very
common among individuals with CHARGE. Abnormalities of
CN function are also common among children with other
causes of growth and/or developmental delay, and are not
specific to CHARGE. “Mental retardation” in Verloes’ criteria
was expanded in our proposal to “developmental delay (DD)/
intellectual disability (ID)/autism spectrum disorder (ASD),”2016 Wiley Periodicals, Inc.recognizing that these are clinical diagnoses whose presentation
and severity varies widely across individuals and whose assess-
ments are complicated when sensory impairments are present.
Hypothalamic-hypophyseal dysfunction is also a common fea-
ture in CHARGE, and occurs with Kallmann syndrome. Since both
CHARGE and Kallmann syndromes are associated with CHD7
pathogenic variants, an individual with a pathogenicCHD7 variant
and hypothalamic-hypophyseal dysfunction should be clinically
evaluated for other features of CHARGE, as pointed out by others
[Jongmans et al., 2009] and discussed in our paper.
It can be challenging to establish diagnostic criteria for genetic
conditions that present with broad phenotypic heterogeneity. In
the era before molecular testing for CHD7 variants in CHARGE
syndrome (i.e., prior to 2004), clinicians relied exclusively3367
3368 AMERICAN JOURNAL OF MEDICAL GENETICS PART Aon the presence or absence of specific features to establish the
diagnosis. It is now possible, however, to clarify whether or not a
sequence variant in CHD7 should be considered pathogenic for
the underlying features. There are specific (and extremely useful)
guidelines for when to test for CHD7 sequence variants in
individuals with CHARGE features [Bergman et al., 2011].
Accurate and meaningful genetic information can lead to im-
proved understanding of etiology, provide accurate recurrence
risks, and help pave the way toward better clinical care. We
advocate incorporating CHD7 sequence variant information into
the diagnostic algorithm, when it is available, since this infor-
mation can improve understanding of disease causation, patho-
genesis, and treatment options. In cases when CHD7 variant
testing is not available, the diagnosis can still be made based on
appropriate clinical assessments.
The American College of Medical Genetics and Genomics
(ACMG) recognizes the complexities of and proposes
guidelines for evaluating potential pathogenicity of sequence
variants [Richards et al., 2015]. Disease-specific databases (e.g.,
www.chd7.org), population frequency, functional and expres-
sion data, phenotype–genotype correlations, review of pub-
lished literature, and review of databases such as Exome
Aggregation Consortium (ExAC), 1000 Genomes, and the
Exome Variant Server from the NHLBI Exome Sequencing
Project (ESP) are all critical to accurate pathogenicity assign-
ment. This discourse about the appropriateness of a combined
clinical and molecular diagnosis for CHARGE is therefore both
relevant and timely.REFERENCES
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